Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Nabi (NABI) -- Ignore unavailable to you. Want to Upgrade?

To: Oak Tree who wrote (283)	9/21/2000 9:38:54 AM
From: Extra Pale	Read Replies (2) \| Respond to of 354

Oak Tree, Reuters 9/19 reported: "Through ten months, the study results found 57 percent fewer cases of Staph aureus disease in these immune-compromised study participants who received the vaccine,... But just two months later, a year out, the reduction was 26 percent." Nabi mgmt argues that vaccine is effective and likely will have better results when applied to populations healthier than the dialysis patients. I recall mgmt stating that 6million patients annually might be targets for vaccine. This gets my attention, especially given Nabi's relative valuation. Before I reload on Nabi I would like to see the BLA filed; and before I mortgage the house I would like to see a quality marketing partner...